Neurocrine Biosciences, Inc.

• How Safe is AbbVie from Niacin’s Woes?

  By Shas Dey - March 21, 2013 | Tickers: ABBV, BIIB, MRK, NBIX

  Niacin is a B vitamin essential for the normal function of the nervous system and the gastrointestinal tract, and used for boosting high density lipoprotein (HDL), the “good cholesterol." Although OTC versions of Niacin are available as daily vitamin supplements, a prescription form called Niaspan from AbbVie Inc. (NYSE: ABBV) is a widely prescribed drug for heart patients. However, recent developments do not look too good for the drug.

  More more »

• Four Important Biotech Stocks Targeting Unmet Needs

  By Streetwise Reports - September 1, 2012 | Tickers: ACOR, AMRN, NKTR, NBIX

  By George S. Mack, The Life Sciences Report

   

  Biotech rallies need catalysts to be sustained. Market moving events include drug approvals, such as a couple of obesity products from VIVUS Inc. and Arena Pharmaceuticals Inc., as well as a product to help control serum lipids from Amarin Corp. Plc (NASDAQ: AMRN). But the major diagnostic feature of a market that might be putting it all together is merger and acquisition more »

• A Case for a Small-cap Biotech Basket

  By John-Erik Koslosky - January 4, 2012 | Tickers: CYTX, NBIX, PDLI

  Small biotech stocks are fun for many reasons. The companies often have noble causes. They aim to treat wretched diseases. And their shares sell for small prices. Sure, many run on borrowed money and spend years deep in red ink. But they give us the potential of a five-bagger, 10-bagger, or even better.

  In the small-cap biotech world, profits are ephemeral, but dreams loom large. That’s why I’ve more »